Similarly, the initial 11 pathways (lysine degradation, prostate cancer, etc.)of HIPK2 were enriched in the high expression group, whereas the remaining nine pathways (glycine serine and threonine metabolism, ribosome, etc.)were enriched in the low expression group. Here, HIPK2 is linked to prostate carcinoma.